Novartis Ag (NVS) Depreciation & Amortization (CF) (2009 - 2026)

Novartis Ag has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $1.2 billion for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 1.09% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $1.2 billion (up 1.09% YoY), while the FY2017 annual figure was $6.3 billion, up 2.54% from the prior year.
• Depreciation & Amortization (CF) came in at $1.2 billion for Q1 2026 at Novartis Ag, up from $1.2 billion in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 billion in Q1 2023 to a low of $1.2 billion in Q1 2025.
• Average Depreciation & Amortization (CF) over 5 years is $1.4 billion, with a median of $1.3 billion recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) climbed 27.14% in 2023 and decreased 29.96% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.5 billion in 2022, then gained by 27.14% to $1.9 billion in 2023, then slipped by 29.96% to $1.3 billion in 2024, then retreated by 10.95% to $1.2 billion in 2025, then advanced by 1.09% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.2 billion in Q1 2026, $1.2 billion in Q1 2025, and $1.3 billion in Q1 2024.